Anti-Infectives

Oral and IV option for MRSA and Pseudomonas aeruginosa^1–3

Indicated for the treatment of the following infections in adults:^1,2

• acute bacterial skin and skin structure infections (ABSSSI)
• community-acquired pneumonia (CAP)

Because of the risk of prolonged, disabling and potentially irreversible serious adverse drug reactions this product must only be prescribed when other antibiotics that are commonly recommended for these infections are inappropriate.^1-2

Situations where other antibiotics are considered to be inappropriate are where:

• there is resistance to other first-line antibiotics recommended for the infection
• other first-line antibiotics are contraindicated in an individual patient
• other first-line antibiotics have caused side effects requiring treatment to be stopped
• treatment with other first-line antibiotics has failed

Consideration should be given to official guidance on the appropriate use of antibacterial agents.⁴

For carbapenem-resistant GNB infections - optimised for the treatment of KPC-CRE^4–8

Indicated in adults for the treatment of:⁴

• Complicated urinary tract infection (cUTI), including pyelonephritis
• Complicated intra-abdominal infection (cIAI)
• Hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP)
• Patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above
• Infections due to aerobic Gram-negative organisms with limited treatment options

Consideration should be given to official guidance on the appropriate use of antibacterial agents.⁴

A single-dose lipoglycopeptide with in vitro activity against MRSA and VRE*^9–10

Indicated in adults and paediatric patients aged 3 months and older for the treatment of:⁹

• Acute bacterial skin and skin structure infections (ABSSSI)

Consideration should be given to official guidance on the appropriate use of antibacterial agents.⁹

*In vitro activity does not necessarily infer clinical effectiveness.

Menarini are supporting ongoing education for HCPs. Please explore our on-demand anti-infective webinars.

Menarini is committed to the fight against AMR by providing effective and innovative solutions to treat resistant infections. Menarini also supports the responsible use of antibiotics aligned to best practice in AMS.